Jonathan Alexander Terrett

USPTO Granted Patents = 36 (Patent Applications = 46)

EPO Patents = 3 (Patent Applications = 30)

Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 154(Granted Patents)

Location History:

Lexington, MA (US) (2022)
Cupertino, CA (US) (2019 - 2023)
Lexington, MS (US) (2023)
Cambridge, MA (US) (2020 - 2024)
South Boston, MA (US) (2024)

Company Filing History:

22 out of 77

Crispr Therapeutics Ag

patents

13 out of 84

Cytomx Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459999 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2025-11-04),

2. 12344656 - Genetically engineered T cells having improved persistence in culture (2025-07-01),

3. 12304968 - T-cells expressing anti-LIV1 chimeric antigen receptor (2025-05-20),

4. 12227763 - Methods and compositions for treating cancer (2025-02-18),

5. 12146157 - Anti-PTK7 immune cell cancer therapy (2024-11-19),

6. 12037616 - Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions (2024-07-16),

7. 11926676 - Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such (2024-03-12),

8. 11753466 - Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof (2023-09-12),

9. 11649438 - Methods and compositions for treating cancer (2023-05-16),

10. 11622977 - Materials and methods for engineering cells and uses thereof in immuno-oncology (2023-04-11),

11. 11548944 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2023-01-10),

12. 11548943 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2023-01-10),

13. 11472875 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2022-10-18),

14. 11471491 - Materials and methods for engineering cells and uses thereof in immuno-oncology (2022-10-18),

15. 11389481 - Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 (2022-07-19),

Title: The Innovative Path of Jonathan Alexander Terrett in Biotechnology

Introduction: Jonathan Alexander Terrett, a prominent inventor based in Cambridge, MA, has made significant contributions to the field of biotechnology with a total of 30 patents to his name. His groundbreaking work has not only advanced scientific research but also paved the way for novel therapeutic interventions.

Latest Patents: Among his recent patents is the creation of a Masked Chimeric Antigen Receptor specific to Tyrosine-Protein Kinase Like 7 (PTK7) and immune cells expressing such constructs. Additionally, he developed Anti-CD166 antibodies, including activatable variants, along with methods for utilizing them in diverse therapeutic, diagnostic, and prophylactic applications.

Career Highlights: Terrett has held key positions at esteemed companies such as CRISPR Therapeutics AG and CytomX Therapeutics, Inc., where his expertise has been instrumental in driving innovation and developing cutting-edge technologies in the biotech industry.

Collaborations: Throughout his career, Terrett has collaborated closely with distinguished professionals in the field, including Demetrios Kalaitzidis and Lawrence Klein, to synergistically combine their skills and knowledge for the advancement of scientific discovery.

Conclusion: Jonathan Alexander Terrett's remarkable portfolio of patents, coupled with his tenure at leading biotech companies and collaborations with top experts, underscores his invaluable contributions to the realm of biotechnology. His innovative spirit and dedication to advancing healthcare solutions continue to inspire and shape the future of scientific innovation.

This text is generated by artificial intelligence and may not be accurate.